Clinical experience with nimotuzumab in Cuban pediatric patients with brain tumors, 2005 to 2007

MEDICC Review

Volumn 11, Issue 3, 2009, Pages 27-33

  Saurez Martínez, Giselle ^a   Cabanas Armada, Ricardo ^b   Zaldivar Santiesteban, Melba ^c   Garnier Ávila, Tania ^c   Iglesias Castillo, Bárbara ^d   Piedra Sierra, Patricia ^a   Castillo, Martha Rios ^b   Longchong Ramos, Martha ^b   Iznaga Escobar, Normando ^a   Lage Dávila, Agústin ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b Juan Manuel Marquez Pediatric Hospital   (Cuba)

^c Hospital Pediatrico Octavio de la Concepcion de la Pedraja   (Cuba)

^d Pepe Portilla Pediatric Hospital   (Cuba)

Author keywords

Biological therapy; Brain cancer; Brain neoplasms; Central nervous system neoplasms; Child mortality; EGF receptor; Immunotherapy; Monoclonal antibodies; Nimotuzumab

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; NIMOTUZUMAB; PROCARBAZINE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; BONE PAIN; BRAIN STEM TUMOR; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPENDYMOBLASTOMA; FEMALE; GLIOBLASTOMA; GLIOMA; HEADACHE; HEPATITIS; HUMAN; HYPERTENSION; HYPOTHALAMUS TUMOR; LIFE EXPECTANCY; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OPEN STUDY; SEIZURE; SIDE EFFECT; SOMNOLENCE; SURVIVAL RATE; SURVIVAL TIME; SYNCOPE;

EID: 68649118150     PISSN: 15557960     EISSN: 15273172     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Strother DR, Pollack IF. Tumors of the Central Nervous System. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincot Williams and Wilkins; 2002. p. 751-814.
2. Lanskoswky P. Manual of Pediatric Hematology Oncology. San Diego: Academic Press; 2000. p. 471-91.
3. Wilne S, Collier J, Kennedy C, Koler K, Grundy R, Walker D. Presentation of childhood CNS tumours: a systematic review and meta-analysis. Lancet Oncol. 2007 Aug;8(8):685-95.
4. Taquechel CO, Corral N, Verdecia M, Legrá R, Psudides A. Tumores del sistema nervioso central en la infancia. MEDISAN. 2003;7(4):30-4.
5. Packer RJ. CNS tumors. In: Agarwal B, Perilongo G, Calaminus G, Eden T, editors. SIOP Education Book; 2007.
6. Jahraus CD, Tarbell NJ. Optic Pathway Gliomas. Pediatr Blood Cancer. 2006 May 1; 46(5):586-96. Review.
7. Broniscer A, Gajjar A. Supratentorial High Grade Astrocitomas and Difusse Brain Stem Glioma: Two Challenges for the Pediatric Oncologist. Oncologist. 2004;9(2):197-206.
8. Macdonald TJ, Rood BR, Santi MR, Vezina G, Bingaman K, Cohen PH, et al. Advances in the Diagnosis, Molecular Genetics and Treatment of Pediatric Embryonal CNS Tumors. Oncologist. 2003;8(2):174-86.
9. Packer RJ, Gurney JG, Punyko JA, Donaldson SS, Inskip PD, Stovall M, et al. Long term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol. 2003 Sep 1;21(7):3255-61.
10. Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical and futuristic perspective. J Neurooncol. 2005 Dec;75(3):253-66.
11. Bowers DC, Gargan L, Weprin BE, Mulne AF, Elterman RD, Munoz L, et al. Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma. J Neurosurg. 2007 Jul;107(1 Suppl):5-10.
12. Packer Roger J. Progress and challenges in childhood brain tumors. J Neurooncol. 2005 Dec;75(3):239-42.
13. Warren KE. Molecularly targeted therapy for pediatric brain tumors. J Neurooncol. 2005 Dec;75(3):335-43.
14. Basel J. Targeting tyrosine kinases in cancer: the second wave. Science. 2006 May 26;312(5777):1175-8.
15. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the Epidermal growth factor receptor: Recovery of antagonistic activity. Immunotechnology. 1997 May;3(1):71-81.
16. World Health Organization Drug Information. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94. 2005;19(4):333.
17. Crombet T, Torres O, Rodríguez V, Menéndez A, Stevenson A, Ramos M, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor in advanced brain tumor patients. Hybridoma. 2001;20(2):131-36.
18. Crombet T, Torres L, Neninger E, Catala M, Solano ME, Perera A, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother. 2003 Apr;26(2):139-48.
19. Crombet T, Osorio M, Cruz T, Roca C, Del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22(9):1646-54.
20. Crombet T, Figueredo J, Catalá M, González S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized antiepidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther. 2006;5(4):375-9.
21. Bode U, Buchen S, Warmuth-Metz M, Pietsch T, Bach F, Fleischhack G. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol. 2007;25(18 Suppl):S2006.
22. Bode U, Windelberg M, Massimino M, Khuhlaeva E, Warmuth-Metz M, Kortmann R, et al. Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents. J Clin Oncol. 2008;26(15 Suppl):S2058.
23. Brade AM, Siu L, Oza AM, Southwood B, De Borja M, Pond G, et al. A phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) TheraCIM-h-R3 (Nimotuzumab) in patients with advanced solid tumors. J Clin Oncol. 2006;24(18 Suppl):S13054.
24. Bebb DG, Brade AM, Smith C, Rorke S, Sherman I. Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. J Clin Oncol. 2008;26(15 Suppl):S3037.
25. Xiao-Dong H, Guo-Zhen X, Lil G, Jun-Lin Y, Tai-Xiang L, Shao-Xiong W, et al. Multi-center Phase II Clinical Trial of h-R3, the Recombined Humanized Anti-Epidermal Factor Receptor Monoclonal Antibody, in Combination with Radiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. Chin J Oncol. 2007;29(3):197-201.
26. ClinicalTrials.gov [homepage on the Internet]. YM Biosciences;[updated 2009 June 3; cited 2009 Feb]. Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma. Available from: http:// www.clinicaltrial.gov/ct2/show/NCT00600054.
27. Ramakrishnan MS, Eswariah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs. 2009 Jan- Feb;1(1):41-8.
28. Reddy BK, Vidyasagar M, Shenoy K, Shenoy A, Viswanath L, Babu G, et al. BIOMAb EGFRTM (Nimotuzumab/h-r3) in Combination with standard of care in squamous cell carcinoma of head and neck (SCCHN). Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S450.
29. Pendharkar D, Gupta S, Pal MK, Hakim S, Rashid T. Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 (nimotuzumab) with chemotherapy- A study of toxicity profile and tolerance. J Clin Oncol. 2007;25(18 Suppl):S14151.
30. Bebb DG, Brade AM, Smith C, Rorke S, Sherman I. Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV nonsmall cell lung cancer unsuitable for radical therapy. J Clin Oncol. 2008 May;26 (15 Suppl):S3037.
31. ClinicalTrials.gov [homepage on the Internet]. YM Biosciences;[updated 2009 Jan 15; cited 2009 Jan 15]. Iressa expanded access Program program. Available from: http://clinicaltrials.gov/show/NCT00034879
32. Okie S. Access before Approval- A Right to Take Experimental Drugs? N Engl J Med. 2006 Aug 3;355(5):437-40.
33. Guideline on compassionate use of medicinal products, pursuant to article 83 of regulation (ec) no 726/2004. London, 19 July 2007. Doc. Ref: EMEA/27170/2006.
34. Ünal E, Sahdev I. Use of gemtuzumab ozogamicin in the treatment of pediatric relapsed/refractory Acute Myeloid Leukemia. Turk J Hematol. 2008 Mar;25(1):36-41.
35. National Cancer Institute [Internet]. Rockville (MD): Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS (US);[updated 2008 May 29; cited 2003 Mar 31]. Available from: http://ctep.cancer.gov.
36. Zeltzer PM, Friedman HS, Norris DG, Ragab AH. Criteria and definition of response and relapse in children with brain tumor. Cancer. 1985;56(7 Suppl):S1824-6.
37. Ciardiello F, Tortora G. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investing Drugs. 2002 Jun;11(6):755-68.
38. Crombet T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, anti-angiogenic and proapoptotic activity of h-R3: A Humanized anti-EGFR antibody. Int J Cancer. 2002 Oct 20;101(6):567-75.
39. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). J Clin Oncol. 2008 Nov 20;26(33):5326-34.
40. Metro G, Mottolese M, Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother. 2008 Oct;9(15):2583-601.
41. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma - A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23(6):1088-95.